UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) April 2, 2009
HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Massachusetts
|
|
1-10730
|
|
04-2882273 |
| |
| (State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer |
| of incorporation)
|
|
File Number)
|
|
Identification No.) |
| |
|
|
| 400 Wood Road Braintree, MA
|
|
02184 |
| |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s
telephone number, including area code 781-848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 5 – Corporate Governance and Management
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS, APPOINTMENT OF
CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
On April 2, 2009, Richard Meelia tendered his resignation from the Board of Directors with
immediate effect. Mr. Meelia was elected to the Board of Directors in 2005 and was serving a term
that expired in 2011. Mr. Meelia is Chairman, President and CEO of Covidien Ltd., a global
healthcare products company. He is resigning from Haemonetics’ Board in order to spend more
professional time on Covidien’s operations.
2